Forest/Biovail Tiazac "Late-Listed" Patent Could Delay Andrx Generic
Executive Summary
Forest may be able to forestall generic competition to Tiazac until mid-2003 as a result of a recently listed patent on the once-daily diltiazem product.
You may also be interested in...
Biovail Tiazac Manufacturing Change Prompts Discussions With FDA
Biovail is considering a manufacturing change for its hypertension drug Tiazac that would strengthen its claim that the product is covered under a recently-listed patent - but may trigger a decision by FDA that the patent cannot be used to block generic competition.
Biovail Tiazac Manufacturing Change Prompts Discussions With FDA
Biovail is considering a manufacturing change for its hypertension drug Tiazac that would strengthen its claim that the product is covered under a recently-listed patent - but may trigger a decision by FDA that the patent cannot be used to block generic competition.
Tiazac appeals court ruling
Miami federal court ruling in favor of Andrx upheld on appeal. The court ruled that Andrx' generic version of Biovail/Forest's Tiazac (diltiazem) does not infringe Biovail's patent No. 5,529,791. Biovail listed a patent (No. 6,162,463) in January, triggering new litigation (1"The Pink Sheet" Feb. 5, p. 27)